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Abstract
In recent years, a number of articles have been published on the treatment of acute pancreatitis in
experimental models and most of them concerned animals with mild disease. However, it is difficult
to translate these results into clinical practice. For example, infliximab, a monoclonal TNF antibody,
was experimentally tested in rats and it was found to significantly reduce the pathologic score and
serum amylase activity and also to alleviate alveolar edema and acute respiratory distress
syndrome; however, no studies are available in clinical human acute pancreatitis. Another
substance, such as interleukin 10, was efficacious in decreasing the severity and mortality of lethal
pancreatitis in rats, but seems to have no effect on human severe acute pancreatitis. Thus, the main
problem in acute pancreatitis, especially in the severe form of the disease, is the difficulty of planning
clinical studies capable of giving reliable statistically significant answers regarding the benefits of the
various proposed therapeutic agents previously tested in experimental settings.
According to the pathophysiology of acute pancreatitis, the efficacy of the drugs already available,
such as gabexate mesilate, lexipafant and somatostatin should be re-evaluated and should be
probably administered in a different manner. Of course, also in this case, we need adequate studies
to test this hypothesis.
In the past few years, several new therapeutic options have
changed the management of acute pancreatitis; for exam-
ple, therapeutic ERCP with endoscopic sphincterotomy in
severe biliary pancreatitis, the use of early antibiotic treat-
ment in necrotizing pancreatitis and the demonstration
that enteral feeding is able to decrease the inflammatory
response. In this paper, we describe new therapeutic treat-
ments which could modify the current approach to acute
pancreatitis in the near future. This is possible only
because we have new information to better understand
the pathophysiological processes of the disease.
We can distinguish three clinical phases regarding the
pathophysiology of acute pancreatitis. There is not very
much information on the initial phase of acute pancreati-
tis in humans and, for the most part, it comes from exper-
imental studies [1]. Of course, it is obvious that we can
obtain good therapeutic results only if we treat the pancre-
atitis as soon as possible. In the early stage of acute pan-
creatitis, within the first week of the start of the
inflammatory process, there is an inappropriate activation
of proteases which, together with microcirculatory disor-
ders, leads to the appearance of necrosis. Subsequently,
these events may be associated with macrophage activa-
tion and progress to necrosis. This is a very dangerous
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stage because gut and biliary bacteria can infect the necro-
sis during the third-fourth week of acute pancreatitis. Mor-
tality is approximately 32% in the early stage (mainly
from organ failure) and 12% in the middle stage (5%
from infection). If the necrosis becomes infected, mortal-
ity is 19% in the third week and 37% in the fourth.
There is experimental and clinical evidence that the time
limit for efficacious medical treatment is no more than 60
hours from the onset of the symptoms of acute pancreati-
tis [2]. Another important aspect in the correct approach
for managing acute pancreatitis is the correct clinical clas-
sification. We should thank Bradley for his efforts in
changing the classification of the disease from a patholog-
ical one to a clinical one [3]. Bradley's paper summarizes
the evolution from the Marseille [4] to the Atlanta [3] clas-
sification system: the Marseille classification recognizes
two morphological stages of pancreatitis: edematous
acute pancreatitis and the necrotizing form and, for this
reason, it is a "pathological classification". The Atlanta
classification distinguishes two forms from a clinical
point of view, including mild acute pancreatitis, without
any complications, and severe pancreatitis characterized
by systemic and local complications such as necrosis,
pseudocysts and distant organ failures.
As in other diseases, the pathophysiological aspects of
acute pancreatitis should guide our therapeutic approach.
On the other hand, we should also consider that the treat-
ment needs to be tailored to each individual patient and
we should also take into account the available resources of
each Institution.
Since 1994, many papers have been published suggesting
good medical therapy for patients with acute pancreatitis
[3,5-12], but unfortunately there is no congruence in the
various guidelines regarding stratification of severity,
diagnosis, treatment and presence of Pancreas Units [13].
In the same way, there are no homogeneous evidence lev-
els in the various guidelines [13]. These differences are
quite surprising because most of the participants are the
same experts who decide on the various guidelines. In
addition, as suggested by Bradley [13], there is the need to
unify the various guidelines. In brief, there is the need to
address the efforts of the guideline writers in order to
unify the various guidelines. One example of the rapid
evolution of the knowledge of acute pancreatitis is the fol-
lowing: the UK guidelines were released in 1998 [5],
revised in 2005 [6] and, after just a few weeks, some
researchers asked to change the new 2005 UK guidelines
[14]. Another problem with the guidelines is that many
clinical practitioners in the same country follow different
guidelines [15] and others do not fully apply them in clin-
ical practice [16]; moreover, in most of the guidelines, the
basic management of acute pancreatitis is not reported:
some examples are control of pain and control of nausea,
vomiting and ileus. First of all, there are no extensive stud-
ies on the pharmacological control of pain in acute pan-
creatitis [17-20]; this is quite surprising due to the
importance of this symptom. Second, there are many ther-
apeutic procedures performed on patients who are not
included in the practical guidelines: for example, contin-
ued gastric suction is often used in treating patients with
acute pancreatitis, even if most of the published studies
limit this approach only to patients with severe disease
[21-23]. Finally, gastric acid secretion inhibition is largely
used in patients with acute pancreatitis, even if there are
very few studies on this issue and the results are not con-
clusive [24,25]. The reason for these discrepancies is that
there is poor homogeneity in the treatment of acute pan-
creatitis.
Regarding the experimental perspectives in the treatment
of acute pancreatitis, we would point out that, in the last
five years, more than 2000 papers on the treatment of
acute pancreatitis in experimental models have been pub-
lished. About a half of these were carried out on edema-
tous pancreatitis and only a few of the substances tested
have been applied in clinical practice. One of these sub-
stances is infliximab, a monoclonal TNF-antibody. It was
tested in 100 rats randomly assigned to 10 groups [26]. In
acute edematous pancreatitis and in severe necrotizing
pancreatitis, the drug significantly decreased serum amy-
lase activity and the histopathological score; moreover, in
the severe forms with necrosis, infliximab ameliorated
both parenchymal and fatty tissue necrosis of the pancreas
and it also alleviated alveolar edema and ARDS-like pul-
monary complications, even if this difference was not sig-
nificant. Another avenue investigated was that of
antioxidant treatment to avoid necrosis as a result of the
fall in cytokine levels. Thus, a particular molecule has
been studied for its antioxidative properties: resveratrol
[27]. It was evaluated in acute pancreatitis induced by tert-
butyl hydroperxide injection. Changes in the pancreata
were much less pronounced in the rats which received res-
veratrol for 8 days prior to injection. In this way, it seems
that pancreatic cells may be prevented from undergoing
structural changes during the experimentally-induced
acute inflammation; we would point out that antioxidant
treatment for acute pancreatitis is a never ending story.
However, the utility of such experimental models may
have some limitations and a full extrapolation of experi-
mental data from laboratory animals to humans must be
done with caution; a paper published in 2001 highlighted
the limitations of experimental models in acute pancrea-
titis [28]. In this regard, we report the example of inter-
leukin-10. In experimental studies, this molecule was
effective [29] in reducing the severity of acute pancreatitis,
but it was not capable of preventing new organ failures in
a clinical setting [30]. On the other hand, polyunsaturatedWorld Journal of Emergency Surgery 2006, 1:16 http://www.wjes.org/content/1/1/16
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fatty acids were able to decrease the severity of experimen-
tal acute pancreatitis and these substances were able to
reduce the length of hospitalization and the duration of
jejunal feeding in humans, even if they were not able to
decrease the number of new complications [31,32]. What
are the problems in carrying out studies on therapeutic
agents in acute pancreatitis? In the last 5 years, only 11
studies have been published on the treatment of severe
human acute pancreatitis and most of them regard early
antibiotic treatment. This happens because it is difficult to
plan clinical studies on acute pancreatitis capable of giv-
ing specific answers regarding the benefits of the various
therapeutic agents proposed in the human clinically
severe form of the disease. Furthermore, there is no trans-
lational research in this field. There is the need to better
design future clinical trials in acute pancreatitis [33]. In
fact, therapeutic trials need to record the time from the
onset of symptoms to intervention and there is the need
of using widely accepted prognostic indices to categorize
the severity of acute pancreatitis. The end-points to use
must be relevant and interpretable; mortality is important
but more work is necessary in developing patient out-
comes. Good alternatives include the measurement of
permanent target organ damage, disability, quality of life,
pain scores, category of intervention, surgery, hospital stay
and return to work, and including patients with a single
etiology of acute pancreatitis or at least only those with a
predominant etiology of the disease in the specific coun-
try. The role of immune-modulation is shown by lexipa-
fant in a study including 290 patients: 151 were in the
lexipafant group and 139 in the placebo group. Four
patients were subsequently excluded (three due to an
incorrect diagnosis and one due to a major violation of
the protocol). The analysis of complications regarded 138
patients in the placebo group and 148 in the lexipafant
group. The analysis of attributable mortality was carried
out in 147 patients of the lexipafant group and in 136 in
the placebo group. The analysis of treatment performed
within 48 hours from the onset of the symptoms of acute
pancreatitis was performed in 104 patients of the lexipa-
fant group and in 95 patients of the placebo group. This
study, performed with an adequately sized sample, has
shown that the antagonism of PAF activity on its own is
not sufficient to ameliorate the systemic inflammatory
response syndrome in severe acute pancreatitis: however,
if we look at the data reported, we cannot exclude the pos-
sibility that lexipafant may have some effect, especially in
patients treated within 48 hours from the onset of symp-
toms which regard a reduction in the appearance of pseu-
docysts and deaths [34].
The trials with infliximab are an example of the "magic
bullet" approach which has typified anti-cytokine trials.
The restoration of homeostasis with a single intervention
belies the complex and coordinated nature of the inflam-
matory response. Deleterious effects have been recorded
when single proximal mediators of the inflammatory
response were blocked: development of anti-DNA anti-
bodies, antinuclear antibodies, anticardiolipin antibod-
ies, antithyroid antibodies, appearance of systemic lupus
erythematosus, neurological signs and symptoms associ-
ated with demyelinating lesions of the central nervous sys-
tem, thyroid dysfunction, arthritis, myositis, systemic
sclerosis, pemphigus vulgaris, vitiligo and carpal tunnel
syndrome. In clinical practice, there is the necessity of not
using "magic" drugs alone; we need more drugs capable of
involving the different aspects of the disease [35]. Further-
more, we must be aware of several autoimmune phenom-
ena in patients treated with cytokine and anticytokine
therapy [36]; we also need to change the way the results of
drug trials are communicated to the medical world [35].
Our needs are mainly the following: a correct scientific
method (clinical trials should be preceded by experimen-
tal and pilot studies in order to confirm the safety and the
correct dosage and to estimate the necessary efficacy of
future trials); improvement of the communication of the
results; the editors must share the responsibility of pub-
lishing well-designed and well-conducted clinical studies
whether or not the results are negative and commercial
influence (the risks associated with dealing with biotech-
nology companies are well-known). Companies can be
under severe pressure to repay the venture capitalists and
shareholders. Thus, there is the need for independent
monitoring of the data and safety in company-sponsored
clinical trials. One example of this assumption may be the
highly debated efficacy of protease inhibitors in human
acute pancreatitis [37]. Ten articles of randomized con-
trolled trials evaluating the effects of protease inhibitors
(aprotinin and gabexate) for acute pancreatitis were
retrieved by systematically searching Medline and the
Cochrane Library and Ovid databases published between
January 1966 and December 2003. The main outcome of
interest was the overall mortality rate from acute pancrea-
titis. When protease inhibitors were given to patients with
mild pancreatitis, the results were not significant; on the
other hand, when these proteins were given to patients
with severe pancreatitis, the mortality rate decreased sig-
nificantly. Several steps may be blocked at the same time
and this might be achieved by using several drug combi-
nations at the same time or by the multiple action of a sin-
gle drug in order to block the protease cascade as well as
the cytokine cascade [2].
Another important aspect for the treatment of acute pan-
creatitis is the prevention of the infection of the pancreatic
necrosis. Enteral feeding plays an important role in this. A
study of 34 severe acute pancreatitis patients shows that
systemic inflammatory response syndrome, sepsis, organ
failure, and ICU stay were globally improved in the enter-
ally-fed patients. The acute phase response and diseaseWorld Journal of Emergency Surgery 2006, 1:16 http://www.wjes.org/content/1/1/16
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severity scores (C-reactive protein, APACHE II) were sig-
nificantly improved following enteral nutrition without
any change in the computed tomography scan scores.
Thus, the conclusion was that enteral feeding modulates
the inflammatory and sepsis response in acute pancreati-
tis and is clinically beneficial. This is the first clinical study
demonstrating the beneficial effect of enteral nutrition in
decreasing the inflammatory and sepsis response in severe
pancreatitis [38]. There is no doubt that it is better to
administer enteral feeding via a gastric tube than via a
jejunal tube [39]. In an another study, a total of
50consecutive patients with objectively graded severe
acute pancreatitis were randomized to receive either gas-
tric or jejunal feeding via a fine bore feeding tube. A total
of 27 patients were randomized to gastric feeding and 23
to jejunal feeding. Clinical differences between the two
groups were not significant. Overall mortality was 24.5%
with five deaths in the gastric group (18.5%) and seven in
the jejunal group (31.8%). The simpler, cheaper, and
more easily used gastric feeding is as good as jejunal feed-
ing in patients with objectively graded severe acute pan-
creatitis. This appears to be a useful and practical
therapeutic approach to enteral feeding in the early man-
agement of patients with severe acute pancreatitis. There is
also no doubt that probiotics associated with enteral feed-
ing may become an alternative therapy replacing early
antibiotic use to prevent infection in severe pancreatitis
[40]. In this regard, there is a study planned as a double-
blind placebo-controlled randomised multicenter trial in
which patients will be randomly allocated to a multispe-
cies probiotic preparation (Ecologic 641) or a placebo; it
will be carried out in 15 Dutch Hospitals. The substance
being studied is administered twice daily through a naso-
jejunal tube for 28 days or until discharge. The inclusion
criteria are the following: adult patients with a first onset
of predicted severe acute pancreatitis (Imrie criteria 3 or
more, CRP 150 mg/L or more, APACHE II score 8 or
more) and the exclusion criteria are post-ERCP pancreati-
tis, malignancy, infection/sepsis caused by a second dis-
ease, intra-operative diagnosis of pancreatitis and use of
probiotics during the study. The substance being studied
administration starts within 72 hours after onset of the
abdominal pain. The primary endpoint is the total
number of infectious complications; the ancillary end-
points are mortality, necrosectomy, antibiotic resistance,
hospital stay and adverse effects of the probiotics. A sam-
ple size of 200 patients was calculated to demonstrate that
probiotic prophylaxis reduces the proportion of patients
with infectious complications from 50% to 30%, with
alpha 0.05 and power 80%. We are awaiting the results of
this study in order to draw a final conclusion on the effec-
tiveness of probiotic prophylaxis in preventing septic
complications in severe acute pancreatitis [41].
Regarding antibiotic therapy, a meta-analysis performed
by Sharma et al. has recently been published which shows
the need for using early antibiotic therapy in order to pre-
vent sepsis and mortality in severe acute pancreatitis [42].
They have shown that antibiotic prophylaxis decreases
sepsis and mortality in patients with acute necrotizing
pancreatitis and they suggested that all patients with acute
necrotizing pancreatitis should receive prophylaxis with
an antibiotic of proven efficacy. The authors concluded
that all patients with acute necrotizing pancreatitis should
receive early antibiotic treatment [42]. It is clear that not
all researchers agree that severe acute pancreatitis should
be treated with early antibiotic administration [43]. After
the publication of the paper of Isenmann R. et al. [43], a
discussion of its validity was begun [44,45]. The main crit-
icisms were that: the pancreatic necrosis was confirmed by
CT criteria in only 58 patients, 5 patients had Staphyloco-
ccus epidermidis coagulase negative strains and the dect-
ection of this species might be considered more a
contamination than a true infection. Once the presence of
infected necrosis was determined, it was not clear if surgi-
cal intervention was immediate or if this was preceded by
the open administration of antibiotics; 28% of the antibi-
otic-treated patients and 46% of the patients in the pla-
cebo group had received an open treatment with
antibiotics. These data could suggest not only the need,
but the inevitability, in everyday clinical practice, of pre-
scribing early antibiotic treatment in the management of
severe necrotizing pancreatitis, either prophylactically or
"on demand". Moreover, why did the authors choose an
antibiotic such as fluoroquinolones which, in a previous
clinical study, did not demonstrate efficacy similar to imi-
penem? And how many patients were fed enterally? [45].
These questions remain unanswered in their paper.
Another open question in the treatment of acute pancrea-
titis is refeeding. It is crucial in patients who have recov-
ered from an acute episode of pancreatitis, but there are
very few studies on this issue. From a practical point of
view, Levy et al. [46] have proposed the following formula
in predicting the pain during refeeding: 0.64 a + 1.11 b +
2.18 c – 9.06, where a = Balthazar's CT score, b = duration
of painful period, c = serum lipase concentration on the
day before refeeding <3 times the upper normal limit and
9.06 = constant. To prevent an acute relapse of acute pan-
creatitis after oral refeeding, the use of lanreotide has been
suggested [47]. In a French study, only 4.3% of the
patients treated with Lanreotide had a recurrence of pain
from acute pancreatitis, but 65.2% experienced adverse
effects from the drug [47]. Since this is an uncontrolled
pilot study, the results should be taken with caution and
should be further confirmed through a double-blind con-
trolled study. From a practical point of view, we also need
to know the exocrine pancreatic function after an acute
episode of pancreatitis in order to cure possible maldiges-World Journal of Emergency Surgery 2006, 1:16 http://www.wjes.org/content/1/1/16
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tion. There are very few studies exploring this aspect [48-
51]. In the our study [51], patients with acute pancreatitis
were studied using the secretin-cerulein test after acute
alcoholic or biliary pancreatitis; pancreatic insufficiency
was significantly more frequent and more severe in alco-
holic pancreatitis than after acute biliary pancreatitis.
These findings, together with the fact that the insufficiency
was also more persistent, suggest that acute alcoholic pan-
creatitis may occur in a pancreas which already has
chronic lesions. Thus, in patients with alcoholic pancrea-
titis, there is the need for enzyme supplementation during
refeeding and this aspect represents an important issue in
nutritional support; however, there are no specific studies
showing the efficacy of enzyme oral supplementation.
In conclusion, the cornerstones for the correct treatment
of acute pancreatitis are those reported in the published
guidelines, but we need hard work to further develop our
knowledge in this fascinating field.
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